Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Guided Therapeutics (GTHP) over the last 14 years, with Q3 2025 value amounting to -$12000.0.

  • Guided Therapeutics' Change in Inventory fell 40000.0% to -$12000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$53000.0, marking a year-over-year decrease of 38181.82%. This contributed to the annual value of $1000.0 for FY2024, which is 9880.95% down from last year.
  • Latest data reveals that Guided Therapeutics reported Change in Inventory of -$12000.0 as of Q3 2025, which was down 40000.0% from -$38000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Change in Inventory ranged from a high of $74000.0 in Q3 2023 and a low of -$47000.0 during Q4 2021
  • Its 5-year average for Change in Inventory is $3750.0, with a median of $0.0 in 2021.
  • Within the past 5 years, the most significant YoY rise in Guided Therapeutics' Change in Inventory was 600000.0% (2023), while the steepest drop was 370000.0% (2023).
  • Quarter analysis of 5 years shows Guided Therapeutics' Change in Inventory stood at -$47000.0 in 2021, then skyrocketed by 170.21% to $33000.0 in 2022, then plummeted by 145.45% to -$15000.0 in 2023, then soared by 80.0% to -$3000.0 in 2024, then crashed by 300.0% to -$12000.0 in 2025.
  • Its Change in Inventory was -$12000.0 in Q3 2025, compared to -$38000.0 in Q2 2025 and -$3000.0 in Q4 2024.